Sugi Predict

Sugi Predict / Compounds / SCHEMBL362258

SCHEMBL362258

SCHEMBL362258

CS(=O)(=O)c1ccc([C@@]2(C(=O)Nc3nccs3)C[C@H]2C2CCCCC2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ GCK P35557 13/20 1.00
▸ TSHR P16473 3/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ MAPT P10636 2/20 0.46
▸ HTT P42858 2/20 0.46
▸ USP2 O75604 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ STAT3 P40763 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ ALDH1A1 P00352 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29225690 1.00 GCK (1.00) GCKTSHRSMN1; SMN2MEN1KMT2A
SCHEMBL1581871 1.00 GCK (1.00) GCKTSHRSMN1; SMN2MEN1KMT2A
SCHEMBL2662321 1.00 GCK (1.00) GCKTSHRSMN1; SMN2MEN1KMT2A
SCHEMBL1581869 1.00 GCK (1.00) GCKTSHRSMN1; SMN2MEN1KMT2A
SCHEMBL1581876 0.99 GCK (0.98) GCKTSHRSMN1; SMN2MEN1KMT2A
SCHEMBL13757055 0.99 GCK (0.98) GCKTSHRSMN1; SMN2MEN1KMT2A
SCHEMBL1582183 0.90 GCK (0.82) GCKTSHRSMN1; SMN2MEN1KMT2A
SCHEMBL2666188 0.90 GCK (0.82) GCKTSHRSMN1; SMN2MEN1KMT2A
SCHEMBL13757036 0.90 GCK (0.81) GCKTSHRSMN1; SMN2MEN1KMT2A
SCHEMBL1581632 0.90 GCK (0.81) GCKTSHRSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 421 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100056460-A1 COMBINATION OF ORGANIC COMPOUNDS ALI MOHAMMED A 2010-03-04 — — US claimed
US-7576108-B2 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY (US) 2009-08-18 — — US claimed
CN-101203244-A Compositions of rennin inhibitor and insulin secernent or insulin sensitizer NOVARTIS AG (CH) 2008-06-18 — — CN claimed
EP-1907004-A2 COMBINATION OF A RENIN INHIBITOR AND AN INSULIN SECRETION ENHANCER OR AN INSULIN SENSITIZER Novartis AG (CH) 2008-04-09 — — EP claimed
WO-2007005763-A2 COMBINATION OF A RENIN INHIBITOR AND AN INSULIN SECRETION ENHANCER OR AN INSULIN SENSITIZER NOVARTIS AG (CH) 2007-01-11 — — WO claimed
EP-3936608-B1 REPROGRAMMING CELLS SCRIPPS RESEARCH INST (US) 2025-05-07 — — EP disclosed
CN-111491631-B Active agent 伦敦玛丽女王大学 2024-06-11 — — CN disclosed
US-11690841-B2 Glycolysis-activating agents for treatment or prevention of disease QUEEN MARY UNIVERSITY OF LONDON (GB) 2023-07-04 — — US disclosed
EP-3936608-A1 REPROGRAMMING CELLS The Scripps Research Institute (US) 2022-01-12 — — EP disclosed
EP-3199623-B1 REPROGRAMMING CELLS SCRIPPS RESEARCH INST (US) 2021-07-28 — — EP disclosed
US-20210095257-A1 REPROGRAMMING CELLS THE SCRIPPS RESEARCH INSTITUTE 2021-04-01 — — US disclosed
US-20200268750-A1 AGENT QUEEN MARY UNIVERSITY OF LONDON (GB) 2020-08-27 — — US disclosed
WO-2007039177-A2 PHENYL- AND PYRIDINYL- 1, 2 , 4 - OXADIAZOLONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (DE) 2007-04-12 — — WO disclosed
WO-2007039175-A1 N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (DE) 2007-04-12 — — WO disclosed
WO-2007039174-A2 BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (DE) 2007-04-12 — — WO disclosed
WO-2007039178-A2 PHENYL-[1,2,4]-OXADIAZOL-5-ONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (DE) 2007-04-12 — — WO disclosed
WO-2007039176-A1 DERIVATIVES OF 2 -AMINTHIAZOLES AND 2-AMINOOXAZOLES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (DE) 2007-04-12 — — WO disclosed
WO-2007039172-A1 PHENYL- AND PYRIDYL-I, 2 , 4 -OXADIAZOLONE DERIVATIVES WITH PHENYL GROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (DE) 2007-04-12 — — WO disclosed
WO-2007039173-A1 CYCLIC N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (DE) 2007-04-12 — — WO disclosed
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY 2006-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200268750-A1 AGENT NFATC1, CX3CR1, CD47 GCK 35/4885TSHR 3366/4885SMN1; SMN2 2927/4885
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators GCK, GCKR, GALK1 GCK 1/4885TSHR 2867/4885SMN1; SMN2 4420/4885
US-11690841-B2 Glycolysis-activating agents for treatment or prevention of disease HK2, PDK1, HK1 GCK 13/4885TSHR 3207/4885SMN1; SMN2 3191/4885
US-20100056460-A1 COMBINATION OF ORGANIC COMPOUNDS REN, IAPP, ACE GCK 95/4885TSHR 1086/4885SMN1; SMN2 3021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.